{"id":40276,"date":"2025-08-28T11:39:11","date_gmt":"2025-08-28T03:39:11","guid":{"rendered":"https:\/\/flcube.com\/?p=40276"},"modified":"2025-08-28T11:39:12","modified_gmt":"2025-08-28T03:39:12","slug":"shandong-boan-biotechnology-reports-8-yoy-revenue-growth-3%e2%80%91year-profit-trend","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40276","title":{"rendered":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend"},"content":{"rendered":"\n<p>China-based Luye Pharma Group\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG: 2186<\/a>) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/6955:HKG\">HKG: 6955<\/a>) on Aug. 27, 2025 released its 2025 interim financial results and business update. The company reported <strong>RMB\u202f393\u202fmillion<\/strong> in total operating revenue, marking an <strong>8\u202f%<\/strong> year\u2011on\u2011year increase, while <strong>product sales revenue rose to RMB\u202f385\u202fmillion<\/strong> (+16\u202f%). Boan Bio has now achieved profitability for three consecutive reporting periods, underscoring the strength of its commercial strategy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-highlights\">Financial Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Interim<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Operating Revenue<\/strong><\/td><td>RMB\u202f393\u202fm<\/td><td><strong>+8\u202f%<\/strong><\/td><\/tr><tr><td><strong>Product Sales Revenue<\/strong><\/td><td>RMB\u202f385\u202fm<\/td><td><strong>+16\u202f%<\/strong><\/td><\/tr><tr><td><strong>Profitability<\/strong><\/td><td>3\u2011year consecutive<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-momentum\">Commercial Momentum<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approved Product Portfolio<\/strong> \u2013 Boan Bio currently markets <strong>four<\/strong> products, with <strong>three<\/strong> already commercialized.<\/li>\n\n\n\n<li><strong>Sales Network<\/strong> \u2013 Over <strong>3,000<\/strong> hospitals and medical institutions nationwide constitute the company\u2019s sales backbone.<\/li>\n\n\n\n<li><strong>Marketing Excellence<\/strong> \u2013 An in\u2011house team of seasoned sales professionals and diversified strategic partnerships fuel the steady 16\u202f% sales lift in the first half of the year.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-r-amp-d-pipeline-amp-funding\">R&amp;D Pipeline &amp; Funding<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biologics License Application (BLA)<\/strong> \u2013 Two projects are under BLA review.<\/li>\n\n\n\n<li><strong>Clinical &amp; Early\u2011Stage Projects<\/strong> \u2013 More than <strong>10<\/strong> projects span from pre\u2011clinical to early\u2011phase clinical trials.<\/li>\n\n\n\n<li><strong>Self\u2011Sustaining Model<\/strong> \u2013 Commercialization of the first wave of R&amp;D products is establishing a stable, self\u2011sufficient revenue stream that will finance future drug development and accelerate innovation timelines.<\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/H2_AN202508271735551214_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202508271735551214_1.\"><\/object><a id=\"wp-block-file--media-bc2b6f3d-6b13-41de-9d8d-d38a3ac71a50\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/H2_AN202508271735551214_1.pdf\">H2_AN202508271735551214_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/H2_AN202508271735551214_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bc2b6f3d-6b13-41de-9d8d-d38a3ac71a50\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Luye Pharma Group\u2019s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40278,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[220,27,1023,1024,219],"class_list":["post-40276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-boan-biotechnology","tag-finanical-reports","tag-hkg-2186","tag-hkg-6955","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong\u2011listed Shandong Boan Biotechnology (HKG: 6955) posted 2025 interim results: RMB\u202f393\u202fm operating revenue (+8\u202f%) and RMB\u202f385\u202fm product sales (+16\u202f%). The company\u2019s four approved products, 3,000\u2011hospital sales network, and robust R&amp;D pipeline of 10+ projects signal continued growth and profitability.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40276\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend\" \/>\n<meta property=\"og:description\" content=\"Hong Kong\u2011listed Shandong Boan Biotechnology (HKG: 6955) posted 2025 interim results: RMB\u202f393\u202fm operating revenue (+8\u202f%) and RMB\u202f385\u202fm product sales (+16\u202f%). The company\u2019s four approved products, 3,000\u2011hospital sales network, and robust R&amp;D pipeline of 10+ projects signal continued growth and profitability.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40276\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T03:39:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-28T03:39:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend\",\"datePublished\":\"2025-08-28T03:39:11+00:00\",\"dateModified\":\"2025-08-28T03:39:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276\"},\"wordCount\":215,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2802.webp\",\"keywords\":[\"Boan Biotechnology\",\"Finanical Reports\",\"HKG: 2186\",\"HKG: 6955\",\"Luye Pharma\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40276#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40276\",\"name\":\"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2802.webp\",\"datePublished\":\"2025-08-28T03:39:11+00:00\",\"dateModified\":\"2025-08-28T03:39:12+00:00\",\"description\":\"Hong Kong\u2011listed Shandong Boan Biotechnology (HKG: 6955) posted 2025 interim results: RMB\u202f393\u202fm operating revenue (+8\u202f%) and RMB\u202f385\u202fm product sales (+16\u202f%). The company\u2019s four approved products, 3,000\u2011hospital sales network, and robust R&D pipeline of 10+ projects signal continued growth and profitability.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40276\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40276#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend - Insight, China&#039;s Pharmaceutical Industry","description":"Hong Kong\u2011listed Shandong Boan Biotechnology (HKG: 6955) posted 2025 interim results: RMB\u202f393\u202fm operating revenue (+8\u202f%) and RMB\u202f385\u202fm product sales (+16\u202f%). The company\u2019s four approved products, 3,000\u2011hospital sales network, and robust R&D pipeline of 10+ projects signal continued growth and profitability.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40276","og_locale":"en_US","og_type":"article","og_title":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend","og_description":"Hong Kong\u2011listed Shandong Boan Biotechnology (HKG: 6955) posted 2025 interim results: RMB\u202f393\u202fm operating revenue (+8\u202f%) and RMB\u202f385\u202fm product sales (+16\u202f%). The company\u2019s four approved products, 3,000\u2011hospital sales network, and robust R&D pipeline of 10+ projects signal continued growth and profitability.","og_url":"https:\/\/flcube.com\/?p=40276","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-28T03:39:11+00:00","article_modified_time":"2025-08-28T03:39:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40276#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40276"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend","datePublished":"2025-08-28T03:39:11+00:00","dateModified":"2025-08-28T03:39:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40276"},"wordCount":215,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40276#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp","keywords":["Boan Biotechnology","Finanical Reports","HKG: 2186","HKG: 6955","Luye Pharma"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40276#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40276","url":"https:\/\/flcube.com\/?p=40276","name":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40276#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40276#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp","datePublished":"2025-08-28T03:39:11+00:00","dateModified":"2025-08-28T03:39:12+00:00","description":"Hong Kong\u2011listed Shandong Boan Biotechnology (HKG: 6955) posted 2025 interim results: RMB\u202f393\u202fm operating revenue (+8\u202f%) and RMB\u202f385\u202fm product sales (+16\u202f%). The company\u2019s four approved products, 3,000\u2011hospital sales network, and robust R&D pipeline of 10+ projects signal continued growth and profitability.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40276#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40276"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40276#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp","width":1080,"height":608,"caption":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40276#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3\u2011Year Profit Trend"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40276"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40276\/revisions"}],"predecessor-version":[{"id":40279,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40276\/revisions\/40279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40278"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}